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Abstract
Background: The diagnosis of Strongyloides stercoralis (S. stercoralis) infection is hampered by the suboptimal sensitivity of
fecal-based tests. Serological methods are believed to be more sensitive, although assessing their accuracy is difficult
because of the lack of sensitivity of a fecal-based reference (‘‘gold’’) standard.
Methods: The sensitivity and specificity of 5 serologic tests for S. stercoralis (in-house IFAT, NIE-ELISA and NIE-LIPS and the
commercially available Bordier-ELISA and IVD-ELISA) were assessed on 399 cryopreserved serum samples. Accuracy was
measured using fecal results as the primary reference standard, but also using a composite reference standard (based on a
combination of tests).
Results: According to the latter standard, the most sensitive test was IFAT, with 94.6% sensitivity (91.2–96.9), followed by
IVD-ELISA (92.3%, 87.7–96.9). The most specific test was NIE-LIPS, with specificity 99.6% (98.9–100), followed by IVD-ELISA
(97.4%, 95.5–99.3). NIE-LIPS did not cross-react with any of the specimens from subjects with other parasitic infections. NIE-
LIPS and the two commercial ELISAs approach 100% specificity at a cut off level that maintains $70% sensitivity.
Conclusions: NIE-LIPS is the most accurate serologic test for the diagnosis of S. stercoralis infection. IFAT and each of the
ELISA tests are sufficiently accurate, above a given cut off, for diagnosis, prevalence studies and inclusion in clinical trials.
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Introduction
Strongyloides stercoralis (S. stercoralis) is a nematode widely
distributed all over the world, in areas where poor hygienic
conditions permit the maintenance of its transmission. In the
human host the infection is characterized by an autoinfective
cycle, that can lead to life-long carriage of the parasite if left
untreated [1]. For this reason, chronically infected patients are
often found even in areas where transmission no longer occurs [2].
Chronic infection is often clinically silent. It is crucial, however,
to detect and treat the infection in order to avoid the risk of the
life-threatening complications (hyperinfection and dissemination)
that can develop in the face of immunosuppression (e.g. underlying
medical conditions and/or iatrogenic [steroids, other immuno-
suppressive agents]) [3].
Proper diagnostic testing is crucial both to identify S. stercoralis-
infected individuals and to evaluate the prevalence of the infection
among populations. One of the main problems with S. stercoralis is
that its overall prevalence is probably underestimated [4], mostly
due to the lack of sensitivity of fecal – based tests that are the most
commonly used assessments for S. stercoralis infection. Serologic
tests are also very useful, but their specificity is variable [5] and
more difficult to assess because of the unreliability of the used
reference test, i.e. microscopy. Discordant (fecal negative –
serological positive) samples cannot be clearly defined. Further-
more, specificity is likely to be variable in different population
groups and to be better in environments where other intestinal
parasites are rare or absent, while sensitivity may be sub optimal in
immunosuppressed patients [6].
An ideal diagnostic tool for S. stercoralis should have a very high
sensitivity when used for screening (i.e. candidates for transplan-
tation, chemotherapy, systemic corticosteroids) as well as to detect
persistence of infection after treatment (therapeutic failure). Ideally
the test should become negative or consistently show a marked
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decrease in titer in a predictable time after successful treatment.
Although some studies document a decline of antibody titer after
effective treatment, a clear cut-off value has yet to be defined
[7,8,9,10]. For a clinical trial, however, a very high specificity is
needed in order to avoid inclusion of false positive subjects.
The main objective of the present study was to assess the
accuracy of five serologic methods for the diagnosis of S. stercoralis
infection in different patient populations. The serologic tools are
intended for use both in highly endemic settings (screening of
subjects at risk for complications, prevalence studies, clinical
diagnosis in adequately equipped laboratories) and in areas of low
or no endemicity (screening and diagnosis of immigrants, travelers,
and autochthonous infection in elderly patients in countries
previously endemic such as in Southern Europe).
Methods
Conduct of the study
The study was carried out in two reference laboratories for
parasitic diseases (CTD Negrar - Verona, Italy and NIAID-NIH,
Bethesda, US) by well-trained staff members. Samples were
selected from a composite study population that is described in
detail below. As fecal based methods are virtually 100% specific
but lack sensitivity [10,11,12], a composite reference standard was
also used (see below) as a suggested procedure for the evaluation of
diagnostic tests when there is no gold standard [13,14].
Study design
The study was designed as a retrospective comparative
diagnostic study on archived, anonymized serum samples.
Sensitivity, specificity and positive and negative predictive values
(PPV, NPV) of the index tests calculated against the primary
reference standard (direct demonstration of Strongyloides larvae in
stools by microscopy or culture) was used as the primary endpoint.
A secondary endpoint was a test’s sensitivity, specificity and
predictive values when compared to a composite reference
standard (as defined below).
Study samples
The study was carried out on fully anonymized, coded serum
samples already available at CTD that were selected randomly,
within each study group outlined below. The archived specimens
were kept frozen at 280uC from the day of the sample collection
and tests were executed within 24 hours of unfreezing.
Inclusion criteria
Serum specimens were selected from a composite patient
population including:
Group I - Subjects of all ages with S. stercoralis larvae in
fecal specimens, identified by microscopy and/or culture
(primary reference standard)
Group II - Subjects with no previous exposure to S.
stercoralis: healthy blood donors and patients of all ages,
born and resident in non-endemic areas of Europe and
with no travel history to endemic countries.
Group III - Subjects with potential, previous exposure to
S. stercoralis but with negative fecal tests for strongyloidiasis:
a) subjects routinely screened for parasites, with no
known parasitic infections.
b) patients with other parasitic infections (see below
for details).
Exclusion criteria
Group I - Hyperinfection syndrome (HS) or dissemi-
nated strongyloidiasis (DS). HIV patients with CD4+
cells ,350/mL
Group II - History of farm work; age .50 years;
previous residence in areas where Strongyloides transmis-
sion was known to occur in past decades
Group III - HIV patients with CD4+ cells ,350/mL.
Participant sampling and sample size
Based on an expected sensitivity of ,90% and specificity of
,95% (Group II) and 90% (Group III), sample sizes were
calculated. Ultimately there were 114 in Group I (the Strongyloides
infected group); 115 specimens for Group II and 170 for Group
III. Within Group III b the parasitic infections diagnosed included:
Schistosoma spp, Trichinella spiralis, Toxocara canis, Fasciola hepatica,
Echinococcus granulosus, Hookworm, Loa, Onchocerca volvulus, Man-
sonella perstans, Wuchereria bancrofti and Trypanosoma cruzi. The study
population is summarized in the STARD flow chart (Supporting
Information Figure S1).
Test methods
Primary reference standard. Direct detection of S. stercor-
alis larvae in stool, either through microscopy of at least three fecal
samples after formol-ether concentration or Baermann, or stool
agar/charcoal culture for S. stercoralis.
Composite reference standard. The subject classification
to this purpose was: Infected (denominator for sensitivity): either
a positive reference (fecal) test OR at least 3 positive results of the 5
serologic tests. Not infected (denominator for specificity): a
negative reference (fecal) test AND ,3 positive results out of the 5
serologic tests.
Index serologic tests. Index serologic tests included three
non-commercial tests: IFAT (CTD) [15], NIE- ELISA [16] and
Author Summary
The diagnosis of Strongyloides stercoralis infection is
usually made by finding larvae of the parasite in the feces.
The larval output is orders of magnitude lower than, say,
the egg output of Ancylostoma duodenale, therefore the
sensitivity of conventional techniques is poor. Sensitivity is
enhanced by specific techniques, but the infection can still
be missed. Several serologic methods (Strongyloides
antibody detection in blood) are considered more sensi-
tive, but they have been assessed so far with fecal tests as
the gold standard, which is obviously unsatisfactory
considering, precisely, their suboptimal sensitivity. Using
a bank of sera from patients surely infected, not infected or
doubtful, we assessed the accuracy of five different
serologic tests also using a composite reference standard,
obtained by combining the results of different tests. The
recently developed NIE-LIPS resulted virtually 100% spe-
cific, with sensitivity .80%. Two commercially available
ELISA tests were also highly specific above a given cut-off.
Cross reactions with other parasitic infections were rarer
than in previous studies. In conclusion, serologic tests are
accurate tools, both for diagnostic purposes and for
prevalence studies. Whether or not they can also be
reliable markers of cure is currently under study.
Accuracy of Serologic Tests for S. stercoralis
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NIE- LIPS [17] and 2 commercially available tests: Bordier
ELISA (Bordier Affinity Products, Switzerland [18], batches
1120S and 1209S, expiry dates August 8th 2013 and December
29th 2013, respectively) and IVD-ELISA (SeroELISA Strongyloides
IgG, IVD Research Carlsbad, CA [19], batch D2852, expiry date
September 9th 2013). Cutoffs for each test were pre-determined
prior to testing.
A brief description of all the methods follows:
N IFAT (CTD – in house method): it detects IgG antibodies
against S. stercoralis; for antigen preparation, intact S. stercoralis
filariform larvae are obtained from a positive charcoal fecal
culture, as it has been described previously [15]. Based on
ROC analysis, samples with antibody titers $1:20 were
considered positives.
N NIE refers to a 31-kDa recombinant antigen derived from a S.
stercoralis L3 cDNA library. NIE-based assays used in this trial
were NIE- ELISA [16] and NIE- LIPS (Luciferase Immuno-
precipitation System) [17]. For the LIPS assay, all data were
corrected for background reactivity. Cut offs for negatives and
positives were based on ROC analysis using sera from stool
positive Strongyloides-infected patients and normal healthy
controls as described [17]. For the NIE-ELISA, a standard
curve was used and values (units/ml) interpolated from that
standard curve [16]. ROC analyses performed previously were
used to establish the negative and positive cutoffs for the NIE-
ELISA. Cut-offs for NIE ELISA and NIE LIPS were $24.13
Units/ml and$1434 Relative Light Units (RLU), respectively.
N Bordier ELISA [18]: it detects Strongyloides IgG antibodies by
using somatic antigens from larvae of Strongyloides ratti.
According to the manufacturer’s instructions, the result is
positive when the absorbance of the analyzed sample is higher
than the absorbance of the weak positive control (provided in
the kit). For the study purpose, in order to be able to compare
results from different sessions, we defined as positives samples
with: absorbance of study sample/absorbance of weak positive
serum$1 (calculated value).
N IVD ELISA [19]: it detects Strongyloides IgG antibodies by
using somatic antigens from larvae of Strongyloides stercoralis.
Positive samples are defined by absorbance greater than 0.2
OD units. For the study purpose, absorbance of study sample/
0.2$1 (calculated value) was used as the cutoff.
Number, training and expertise of the persons executing
and reading the index tests and the reference standard
All index tests were executed by senior staff of the participating
laboratories that are reference laboratories for parasitology in the
respective countries. The (primary) reference standard tests had
been carried out by senior staff of CTD lab who were in charge of
fecal and blood parasite microscopy and stool culture for
Strongyloides.
IFAT (involving subjective reading) was independently carried
out by two senior staff members of CTD laboratory. Discordant
results were read by a third senior staff of CTD. The two
commercial ELISA tests were also performed at CTD.
NIE-ELISA and NIE-LIPS were performed at NIAID-NIH (the
laboratory which developed the method) by a senior staff member
with help from a member of the University of Salta (Argentina).
Blinding
All sera were re-coded by persons not directly involved in the
study. Laboratory staff involved in the study had no access to the
source codes and therefore were blinded as of the results of the
previous reference tests, as well as of the results of the other index
tests.
Statistical analysis
For both the primary and secondary endpoints, the sensitivity of
each index test was calculated as the proportion of positive results
over all positive samples at the primary reference test. It was
further calculated for different cut-off levels for each test.
Uncertainty was quantified using the 95% confidence intervals.
Specificity was first calculated over all sera from patients of Group
II (subjects with no previous exposure to S. stercoralis), then on the
whole control group, as the proportion of negative results of the
index tests. It was further calculated for pre defined cut-off levels of
each test. Uncertainty was quantified the same way as above. The
corresponding ROC curves were plotted for each of the five index
tests. Predictive values (PPV, NPV) were then estimated for
different, theoretical prevalence or pre-test probabilities, both for
the dichotomous test results and for the different cut-off values
according to the ROC curves. Confidence interval (95%) at
different cut-off levels of the index tests were calculated by
bootstrap method using 2000 samples. The Kappa test (with its
95% confidence interval) was performed to assess concordance
between each index test and the primary and the composite
reference standards, respectively, as well as between pairs of index
tests. Cohen’s Kappa measure was used to assess the agreement as
follows: K,0, no agreement; K= 0–0.20, poor agreement;
K= 0.21–0.40, fair agreement; K=0.41–0.60, moderate agree-
ment; K= 0.61–0.80, substantial agreement; and K=0.81–1.00,
nearly perfect agreement [20,21]. Multiple logistic regression
analysis was used to study the variation of main outcome variables
according to potential predictor variables such as age; sex;
continent of origin.
Ethical issues
Samples were anonymously coded, unlinked from any infor-
mation identifying the source individuals. Although the study was
retrospective and no action on patients was involved, the study
protocol was nevertheless submitted to the Ethics Committee of
the Coordinating Site (Comitato Etico Provinciale di Verona) for
approval. The latter acknowledged the study protocol and
formally authorized the study (protocol n. 13286/09.11.01 of
24th April, 2012).
Results
Results are reported according to the STARD checklist
(Supporting Information Table S1). The sample selection and
the laboratory analyses were performed during the second
semester of 2012. The median age of the whole study population
was 39 y (range, 1–86, interquartile range 26), with no relevant
differences between subgroups. As for the continent of origin, of
the 114 patients of Group I, 56 (49%) came from Europe, 27
(24%) from Africa, 17 (15%) from Asia and 14 (12%) from South
America. All 115 controls of Group II were from Europe, while, of
the 170 controls of Group III, 51 (30%) were from Europe, 75
(44%) from Africa, 16 (9%) from Asia and 28 (17%) from South
America.
The proportion of samples with at least 3 positive serologic tests
within each study group is summarized in Table 1. There were
399 pre-treatment samples overall, 114 from subjects with a
positive fecal test (the denominator for sensitivity based on the
primary reference standard) and 285 from subjects with a negative
fecal test (the denominator for specificity). Of the 114 S. stercoralis
Accuracy of Serologic Tests for S. stercoralis
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stool-positive subjects, 107 (93.9%) had at least three positive index
tests.
According to the composite reference standard, subjects
classified as infected were 130 overall. Those classified as non-
infected were 269 comprised of 115 from Group II and 154 from
Group III. Of the latter, 62 subjects had another parasitic infection
diagnosed (Group III b) and the remaining 92 had none (Group
III a).
Accuracy
The overall accuracy of index tests using the primary reference
standard for sensitivity (subjects with positive fecal results), and
control Group II for specificity (subjects with negative fecal results
and no previous, potential exposure to S. stercoralis) is summarized
in Table 2. The most sensitive test was the IFAT, with a sensitivity
93.9% (IC 89.5–98.3), followed by IVD ELISA with a sensitivity
91.2% (86.0–96.4). The most specific test was LIPS, with
specificity 100%, followed by IVD ELISA with specificity 99.1%
(97.4–100) and Bordier ELISA with specificity 98.3% (95.9–100).
Of 170 subjects of Group III (negative fecal tests and potential
previous exposure to S. stercoralis), 70 (41.2%) had at least one
positive index test result (Table 3). Sixteen of the 70 specimens
(22.9%) were probable true positives according to the composite
reference standard, corresponding to 9.4% of probable cases
detected by serology among subjects with a negative fecal result
and potential exposure (Table 1). Therefore, 16 subjects initially
classified as controls were subsequently found positive in at least 3
serologic tests; these were then included among cases when based
on the composite reference standard. Five of the 16 samples were
initially classified as Group III b, as they had other parasitic
infections. Three of them were from Africa and had a filarial
infection (with Mansonella perstans, Loa and Onchocerca volvulus,
respectively), one from South America (with Chagas disease) and
one from Europe (with Toxocara). Three samples were positive in 3
out of the 5 serologic tests for Strongyloides, while the remaining two
(with Onchocerca and Chagas, respectively) were positive in all tests
for Strongyloides. Eleven of the 16 samples were initially classified as
belonging to Group III a, as they had no other parasitic infection
diagnosed. Three of them were from Africa, 4 from South
America, 4 from Europe. All control samples had been submitted
for routine parasitological and serologic screening tests carried out
at CTD. Five of these 11 tested positive in all serologic tests for
Strongyloides, 5 were positive in 4 tests, and 1 was positive in 3 of the
serological tests.
The number of positive results in this group for the different
tests and the proportion of true positives according to the
composite reference standard is also reported in Table 3. NIE
LIPS had the highest proportion of true positives (12/13 or
92.3%), followed by IVD ELISA (16/22 or 72.7%).
The test accuracy on the whole study population, according to
both reference standards, is summarized in Table 4. Figures on
sensitivity are similar for both reference standards. As far as
specificity is concerned, NIE LIPS is, again, the most specific test
(95.4% and 99.6% according to primary and composite reference
standard, respectively), followed by the IVD ELISA (91.9% and
97.4%) and the Bordier ELISA (88.8% and 94.1%).
Cross reactions with other parasitic infections
Analyzing in detail Group III b (Table 5), LIPS did not cross-
react with any of the specimens from subjects with other parasitic
infections; IFAT with 7/62 (11.3%) specimens; IVD ELISA with
6/62 (9.7%) specimens; NIE-ELISA with 6/62 (9.7%) specimens;
Bordier ELISA with 7/62 (11.3%) specimens. For 5/62 specimens
(8.1%), two index tests gave false positive results, for 16/62
specimens (25.8%) only one test out of the five was false positive,
while for the remaining 41 specimens (66.1%) all five tests were
Table 1. Proportion of samples with $3 positive serologic tests.
Study Group
$3 positive
serologic tests (%)
,3 positive
serologic tests (%) Total
Group I Samples from patients with Ss larvae in stool
(denominator for sensitivity, primary reference standard)
107 (93.9)* 7 (6.1)* 114 (100)
Group II Samples from patients with no Ss larvae in stool,
unexposed (denominator for specificity, primary reference standard)
0(0) 115 (100)‘ 115 (100)
Group III Samples from patients with no Ss larvae in stool, exposed
Group III a) Samples from patients with no Ss larvae in stool, exposed, no other parasites 11 (10.7) 92 (89.3) 103 (100)
Group III b) Samples from patients with no Ss larvae in stool, exposed, other parasites
diagnosed
5 (7.5) 62 (92.5) 67 (100)
16 (9.4)* 154 (90.6)‘ 170 (100)
TOTAL 123 (30.8) 276 (69.2) 399 (100)
infected according to primary reference standard: N. 114.
not infected according to primary reference standard: N. 115+170 = 285.
*infected according to composite reference standard: N. 130.
‘not infected according to composite reference standard: N. 269.
doi:10.1371/journal.pntd.0002640.t001
Table 2. Test accuracy on samples from subjects with certain
diagnosis (denominator for sensitivity: 114 subjects with Ss
larvae in stool; denominator for specificity: 115 subjects with
no Ss larvae in stool and no exposure).
TEST Sensitivity (IC 95%) Specificity (IC 95%)
NIE ELISA 75.4 (67.5–83.3) 94.8 (90.7–98.9)
NIE LIPS 85.1 (78.6–91.6) 100.0 (100.0–100.0)
IFAT 93.9 (89.5–98.3) 92.2 (87.3–97.1)
IVD ELISA 91.2 (86.0–96.4) 99.1 (97.4–100.0)
BORDIER ELISA 89.5 (83.8–95.1) 98.3 (95.9–100.0)
doi:10.1371/journal.pntd.0002640.t002
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negative. As for the individual parasites, Mansonella perstans caused
the highest proportion of false positive reactions.
ROC curves. The test with the widest area under the curve
(at the composite reference standard) was IVD ELISA (0.985)
(Figure 1), followed by Bordier ELISA (0.977) (Figure 2). LIPS
(Figure 3) was virtually 100% specific at a cut-off value of 1388, at
which sensitivity remained very high (84.6%). IVD reached the
same specificity at a cut-off value of 2.53, at which sensitivity
dropped to 79%. Bordier ELISA reached 100% specificity at a
cut-off value of 2.23, corresponding to a sensitivity of 70%. IFAT
(Figure 4) was 99% specific at cut-off 6 (1/160 titer) corresponding
to a sensitivity of 64%. NIE ELISA (Figure 5) was 99% specific at
cut-off 76.5 corresponding to a sensitivity of 45%. ROC curves for
the five tests using the primary reference standard are reported in
Supporting Information Figures S2, S3, S4, S5, S6. Accuracy for
the different cut-off values of the tests is reported in detail in
Supporting Information Table S2.
Predictive values
Positive and negative predictive values (PPV, NPV) were
estimated, based on the test accuracy and on different theoretical
prevalence rates or pre-test probabilities (Supporting Information
Table S3 and S4). Estimations were first made using the accuracy
data summarized in Table 2, obtained from samples with an
established diagnosis (Supporting Information Table S3). Further
estimations were made using accuracy data summarized in Table 4
b, obtained by using the composite reference standard on the
whole study population (Supporting Information Table S4).
According to both standards, LIPS was the test with the highest
PPV (100% and 69.6%, respectively) even at the lowest prevalence
(1%), at which NPV was 99.8% (with both standards). IFAT and
IVD ELISA had a NPV $99% up to a prevalence of 10%.
Concordance
IVD ELISA showed the highest overall concordance with the
composite reference standard (0.90, IC 0.86–0.95), followed by
LIPS (0.87, IC 0.82–0.92), Bordier ELISA (0.84, IC 0.79–0.90),
IFAT (0.78, IC 0.71–0.84) and NIE-ELISA (0.63, IC 0.55–0.72).
The concordance between pairs of tests is reported in Supporting
Information Table S5.
The highest concordance was between IVD ELISA and Bordier
ELISA (0.83, IC 0.78–0.89), followed by that between IVD ELISA
and LIPS. The lowest concordance was between IFAT and NIE
ELISA (0.50, IC 0.41–0.59).
Logistic regression
Age slightly correlated with infection, both using the primary
reference standard (OR 1.020, IC 1.006–1.033) and the composite
reference standard (OR 1.018, IC 1.006–1.031). Europe as the
continent of origin as opposed to Asia correlated negatively with
infection using the primary (OR 0.311, IC 0.131–0.737) as well as
the composite reference standard (OR 0.326, IC 0.140–0.761).
Discussion
With the present study we assessed the accuracy of five serologic
tests for S. stercoralis not only against a primary reference standard
(using fecal-based positivity), but also against a composite reference
Table 3. Test results on samples from subjects with no Ss
larvae in stool and risk of exposure (170 samples).
TEST N positive (%)
N true positive (%) according to
composite reference standard
NIE ELISA 24 (14.1%) 6 (25.0%)
NIE LIPS 13 (7.6%) 12 (92.3%)
IFAT 41 (24.1%) 16 (24.1%)
IVD ELISA 22 (12.9%) 16 (72.7%)
BORDIER ELISA 30 (17.6%) 16 (53.3%)
ANY TEST 70 (41.2%) 16 (22.9%)
doi:10.1371/journal.pntd.0002640.t003
Table 4. Test accuracy on the whole study population.
a) Primary ref standard (114 infected, 285 uninfected)
IC95% IC95%
TEST Sensitivity LL UL Specificity LL UL
NIE ELISA 75.44 67.54 83.34 89.47 85.91 93.04
NIE LIPS 85.09 78.55 91.63 95.44 93.02 97.86
IFAT 93.86 89.45 98.27 82.46 78.04 86.87
IVD ELISA 91.23 86.04 96.42 91.93 88.77 95.09
BORDIER ELISA 89.47 83.84 95.11 88.77 85.11 92.44
b) Composite ref standard (130 infected, 269 uninfected)
IC95% IC95%
TEST Sensitivity LL UL Specificity LL UL
NIE ELISA 70.77 62.95 78.59 91.08 87.67 94.48
NIE LIPS 83.85 77.52 90.17 99.63 98.90 100.00
IFAT 94.62 90.74 98.50 87.36 83.39 91.33
IVD ELISA 92.31 87.73 96.89 97.40 95.50 99.30
BORDIER ELISA 90.77 85.79 95.75 94.05 91.23 96.88
doi:10.1371/journal.pntd.0002640.t004
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standard. This composite (potentially operational) reference
standard allowed a more realistic classification of cases and
controls, even though it carries a minor risk of misclassifying
samples as false positives. All patients of Group II (most probably
not exposed to S. stercoralis) consistently showed sero-negativity (i.e.
not infected) according to the composite reference standard. If we
consider only those with a positive fecal test as the denominator,
almost 94% had at least three positive index tests (the required
criterion to be classified as infected according to the composite
reference standard).
Test accuracy
The test with the highest specificity was NIE-LIPS, a test that
virtually does not cause any false positive results. This can be an
ideal test for clinical diagnosis, inclusion in clinical trials and
prevalence studies, as its PPV is very high even at very low
prevalence (1%). As far as predictive values are concerned (Tables
S3 and S4), as ours was not a population-based study, we could
only able make estimations based on different theoretical
prevalences. The two reference standards used for accuracy did
not appear to influence NPV (as sensitivity was very similar with
Figure 1. ROC curve for IVD ELISA (composite reference
standard).
doi:10.1371/journal.pntd.0002640.g001
Figure 2. ROC curve for Bordier ELISA (composite reference
standard).
doi:10.1371/journal.pntd.0002640.g002
Table 5. Cross reactions with other parasites (Group III b: 62 subjects).
N false positives (FP)
Parasite IFAT NIE LIPSNIE ELISA Bordier IVD
Total FP
samples
Total FP
reactions
TOTAL
reactions
% FP
reactions
Echinococcus 1 0 0 0 0 1 1 25 4.0%
Fasciola 1 0 0 0 1 2 2 25 8.0%
Loa 1 0 1 0 1 2 3 20 15.0%
HW 1 0 0 0 0 1 1 30 4.0%
HW plus Trichinella 0 0 0 1 1 1 2 5 40.0%
Trichinella 1 0 0 1 1 3 3 30 10.0%
Mansonella 1 0 1 1 0 2 3 20 20.0%
Onchocerca 0 0 0 1 0 1 1 10 10.0%
Toxocara 0 0 1 1 0 1 2 45 4.4%
Chagas 0 0 1 0 0 1 1 40 2.5%
Schistosoma 1 0 2 1 1 5 5 50 10.0%
Wuchereria 0 0 0 1 1 1 2 15 13.3%
TOTAL FP 7 0 6 7 6 21 26 315 8.4%
TOTAL samples 62 62 62 62 62 62
% false positives 11.3% 0% 9.7% 11.3% 9.7% 33.9%
NB Total number of samples differs from Figure 1 (Group III b = 67), as 5 subjects were found positive in at least 3 serologic tests for Strongyloides and then classified as
cases according to the composite reference standard.
doi:10.1371/journal.pntd.0002640.t005
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both standards for each test), while PPV, not surprisingly, was
higher when accuracy was estimated using the primary standard
for cases and clearly unexposed (Group II) individuals as controls.
For the purpose of screening of high risk groups (i.e., patients
candidate to immunosuppressive treatment), the most suitable tests
were IFAT and the two commercial ELISA, that maintain a NPV
close to or higher than 99% up to a prevalence of 10%, regardless
the reference standard used for the estimations. For higher
prevalence, no test would safely exclude the infection, and two
alternative options could be a screening with two different tests, or
a presumptive treatment.
Cross reactions
LIPS, challenged with specimens from patients with several
different parasitic infections, confirms, even in this group, its
excellent specificity. The other tests gave a variable proportion of
false positive results, but less than previously reported (all previous
studies relied exclusively on fecal tests as reference standard).
ROC analysis, choice of a test cut-off for inclusion in
clinical trial
ROC analysis (Figures 1–5) provides indications of a suitable
cut-off for each test, in order to reach or approach a 100%
certainty of infection for positive results, obviously at the expenses
of some loss of sensitivity. We can thus propose a suitable cut-off
level for each test for inclusion in a clinical trial (when a certainty
or at least a very high probability of infection is required). NIE
LIPS appears to be the best test for this purpose. IFAT loses
sensitivity when gaining specificity at the optimal cut off for
inclusion (titer 1/160). The two commercially available ELISA
tests (IVD and Bordier, in this order) showed reliable results in
terms of accuracy and can also be used for inclusion in trials at a
cut-off of, respectively, $2.5, $2.2 at which they approach 100%
specificity, while maintaining.70% sensitivity. Such standard and
available tests could be used both in clinical and public health
practices. It must be mentioned, however, that tests based on
crude antigen may be difficult to ensure optimal reproducibility
among different batches. We strongly recommend laboratories
using these tests to put into place clear quality control methods.
Study limitations
This study has the potential limitations inherent to a retrospec-
tive study design. Some quite relevant data were missing for some
of the control subjects (i.e. the continent of exposure when/if it did
not coincide with the continent of origin). Moreover, as
parasitological methods are not 100% sensitive, also for other
parasitic infections, it may well be that some infections were
missed in control subjects exposed, which may have caused cross
reactivity. While we believe that subjects were better classified
using the composite reference standard, we cannot exclude a
possible misclassification of some of them.
Conclusion and further research needs
The issue of serology as a marker of cure remains an open
question. If we were to rely on fecal-based diagnosis alone, we may
Figure 4. ROC curve for IFAT (composite reference standard)
(numbers correspond to titers, 3 =1/20 to 9=1/1280).
doi:10.1371/journal.pntd.0002640.g004
Figure 5. ROC curve for NIE-ELISA (composite reference
standard).
doi:10.1371/journal.pntd.0002640.g005
Figure 3. ROC curve for NIE-LIPS (composite reference
standard).
doi:10.1371/journal.pntd.0002640.g003
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wrongly consider cured a patient whose parasite load after
treatment is too low to be detected. Thus, an evaluation of
serologic tests to assess cure is currently underway. A prospective
study that will include PCR on fecal samples is also planned. The
ultimate aim is to identify the optimal diagnostic strategy for S.
stercoralis for clinical and epidemiological purposes.
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